Update on Molecular Classification and Individualized Treatments of Genitourinary Tumors (Ongoing)

Posted On 2020-04-07 09:36:53



This Focused Issue “Update on Molecular Classification and Individualized Treatments of Genitourinary Tumors” is edited by Prof. Rodolfo Montironi from Polytechnic University of the Marche Region, Italy, Dr. Alessia Cimadamore from Polytechnic University of the Marche Region, Italy, Prof. Antonio Lopez-Beltran from University of Cordoba, Spain, Prof. Marina Scarpelli from Polytechnic University of the Marche Region, Italy and Prof. Liang Cheng from Indiana University School of Medicine, USA.

Rodolfo Montironi, MD and IFCAP, obtained his medical degree at the Medical School of the University of Ancona, Italy in 1976, the board certificate in pathology and laboratory medicine at the University of Parma, Italy, in 1979, and the board certificate in clinical oncology at the University of Ancona in 1982. He received his advanced training in pathology in several British institutions under the supervision of world leaders in pathology, in particular at Hammersmith Hospital, London, UK, with Dr. John G. Azzopardi in 1979.

Rodolfo is International Fellow of the College of American Pathologists. He is Professor of Pathology at the Medical School of the Polytechnic University of the Marche Region, and, Director of the Uropathology Program, United Hospitals, Ancona, Italy. He is a Past President of the International Society of Urological Pathology. He is the Chairman of the ESUP (EAU Section of Uropathology). He is a member of different international societies of pathology and of urology, including the European Society of Pathology and European Association of Urology.

Rodolfo’s work is centred in genitourinary tumour pathology. He is an author or co-author of more than 800 publications in peer-reviewed international journals and of more than 30 chapters in books in the field of genitourinary tumour pathology. He has been a regular invited speaker at all major national and international pathology meetings. He organised and co-organised several international courses on genitourinary tumour pathology. Rodolfo serves on the editorial boards of several international pathology and urology journals, including European Urology, European Urology Focus and European Urology Oncology.

Alessia Cimadamore, MD, is pathologist at the Pathological Anatomy and Histopathology at United Hospitals, Ancona, Italy. She obtained her medical degree at the Medical School of the University of Ancona, Italy in 2014. During her residency, she has received advanced training in the field of Genito-urinary pathology being involved in important research projects and collaborations with world leaders in the filed, in particular with Professors Rodolfo Montironi, Antonio Lopez-Beltran and Liang Cheng.

Alessia’s research work is centred in genitourinary tumour pathology, with particular interest in PD-L1 expression in bladder and kidney cancers in relation with prognosis, predictive value and immunotherapy response. In 2018, as part of her PhD, she has started a research project on genetic alterations in renal cell carcinoma and their application in liquid biopsy.

During her four-years of research activity, she contributed as author or co-author to complete more than 50 publications in peer-reviewed international journals and more than 30 book chapters in the field of genitourinary tumour pathology. She has been invited as speaker at national and international pathology meetings. She is a member of different international societies of pathology and of urology, including the European Society of Pathology and GenitoUrinary Pathology Societies.

Antonio Lopez-Beltran
Currently I am Director of Anatomic Pathology Service for Champalimaud Clinical Center, in Lisbon, Portugal. Prior to this role I was Director of Anatomic Pathology for Althia Health in Barcelona and Full Professor of Anatomic Pathology at the University of Cordoba. Prior to that post I spent 27 years at the University of Cordoba, Spain where I created The Uro-Oncology Research Lab. I also was the Director of such lab where I designed and implemented novel molecular technics to evaluate prognostic features of bladder and prostate cancer. Through the years we discovered and/or validated some biomarkers of clinical utility, mostly tissue and urine related. Studies from my lab have granted me to be a “Highly Cited Author” by the Institute of Scientific Information with h-index of 61. Beginning may career, I received the medical degree, at the University of Seville in 1979, then I completed the residency program in Anatomic Pathology until 1982 and I received a PhD in Experimental Pathology at the University of Cordoba in 1984. I have been also visiting physician pathologist at the pathology service of the University College (London, UK, 1986 (6 months), Roswell Park Cancer Institute (Buffalo, NY, 1987-1989, 2 years), and Mayo Clinic (Rochester, MN, 1995, 6 months). Finally, I am member of several international pathological organizations and the current Chair of the European Working Group on Urologic Pathology of the European Society of Pathology.

Marina Scarpelli, MD, obtained her medical degree at the Medical School of the University of Ancona, Italy in 1976, the board certificate in pathology and laboratory medicine at the University of Parma, Italy, in 1980. She received her advanced training in pathology in several British institutions under the supervision of world leaders in pathology, in particular at Hammersmith Hospital, London, UK and Institute of Neurological Sciences, Department of Neuropathology, University of Glasgow.

Marina is Professor of Pathology at the Medical School of the Polytechnic University of the Marche Region, and, Director of the Institute of Pathological Anatomy, United Hospitals, Ancona, Italy.

Marina’s work is centred in genitourinary tumour pathology. She is an author or co-author of more than 300 publications in peer-reviewed international journals and of chapters in books in the field of genitourinary tumour pathology. She has been a regular invited speaker at major national and international and national pathology and urology meetings.

Dr. Liang Cheng is the inaugural Virgil H. Moon Endowed Professor of Pathology and Urology at Indiana University School of Medicine, Indianapolis, Indiana, USA. Currently, he is Chief of the Genitourinary Pathology Service, Director of the Urologic Pathology Fellowship, and Director of Molecular Diagnostics and Molecular Pathology Laboratories. Dr. Cheng is board certified in Molecular Genetic Pathology, Anatomic and Clinical Pathology by the American Board of Pathology. Dr. Cheng has received numerous prestigious awards including the Stowell-Orbison Award from the United States and Canadian Academy of Pathology and the Koss Medal Award from the International Society of Urological Pathology (ISUP). Dr. Cheng received the Arthur Purdy Stout Prize from the Arthur Purdy Stout Society of Surgical Pathologists in recognition of outstanding contributions to the field of surgical pathology for a surgical pathologist less than 45 years old. Dr. Cheng has published over 1000 peer-reviewed SCI articles in high-impact scientific journals. His published work has been cited more than 43,000 times (ISI Web of Science h-index: 104). He is also the author of over 100 book chapters and several books, including Bladder Pathology, Urologic Surgical Pathology, Essentials of Anatomic Pathology, Molecular Genetic Pathology, Molecular Surgical Pathology, and Atlas of Anatomic Pathology (Series Editor). Currently, he is an active member of over 30 Editorial Boards, including Molecular Cancer (Associate Editor), Human Pathology (Senior Associate Editor), American Journal of Surgical Pathology, Modern Pathology, Urologic Oncology. He is currently the Editor-in-Chief of Expert Review of Precision Medicine and Drug Development.

Focused issue outline:

  1. Editorial
  2. Where we are now and where we will go
  3. Towards a new WHO classification of genitourinary tumors, with emphasis on kidney cancer
  4. Bladder neoplasms: will a morphological classification become obsolete?
  5. Prostate cancer grading: Will “Gleason” survive?
  6. TNM staging towards a personalized approach: What will the future be like?
  7. Individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?
  8. Artificial intelligence in digital prostate cancer: a roadmap to routine use in clinical practice
  9. Prostate cancer diagnosis and treatment: future role of confocal microscopy

Disclosure:

The series “Update on Molecular Classification and Individualized Treatments of Genitourinary Tumors” was commissioned by the editorial office, Translational Andrology and Urology without any sponsorship or funding. Rodolfo Montironi, Alessia Cimadamore, Marina Scarpelli, Antonio Lopez-Beltran and Liang Cheng are serving as the unpaid Guest Editors for the focused issue.